<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:38:10Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7093052" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7093052</identifier>
        <datestamp>2020-03-30</datestamp>
        <setSpec>jcem</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Endocrinol Metab</journal-id>
              <journal-id journal-id-type="iso-abbrev">J. Clin. Endocrinol. Metab</journal-id>
              <journal-id journal-id-type="publisher-id">jcem</journal-id>
              <journal-title-group>
                <journal-title>The Journal of Clinical Endocrinology and Metabolism</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0021-972X</issn>
              <issn pub-type="epub">1945-7197</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
                <publisher-loc>US</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7093052</article-id>
              <article-id pub-id-type="pmcid">PMC7093052</article-id>
              <article-id pub-id-type="pmc-uid">7093052</article-id>
              <article-id pub-id-type="pmid">31628465</article-id>
              <article-id pub-id-type="doi">10.1210/clinem/dgz103</article-id>
              <article-id pub-id-type="publisher-id">dgz103</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Research Articles</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00250</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effects of Peptide YY on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7599-0166</contrib-id>
                  <name>
                    <surname>Izzi-Engbeaya</surname>
                    <given-names>Chioma</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jones</surname>
                    <given-names>Sophie</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Crustna</surname>
                    <given-names>Yoshibye</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Machenahalli</surname>
                    <given-names>Pratibha C</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Papadopoulou</surname>
                    <given-names>Deborah</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Modi</surname>
                    <given-names>Manish</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Panayi</surname>
                    <given-names>Christos</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Starikova</surname>
                    <given-names>Jessica</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Eng</surname>
                    <given-names>Pei Chia</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Phylactou</surname>
                    <given-names>Maria</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mills</surname>
                    <given-names>Edouard</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yang</surname>
                    <given-names>Lisa</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6740-8471</contrib-id>
                  <name>
                    <surname>Ratnasabapathy</surname>
                    <given-names>Risheka</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sykes</surname>
                    <given-names>Mark</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Plumptre</surname>
                    <given-names>Isabella</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Coumbe</surname>
                    <given-names>Ben</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wing</surname>
                    <given-names>Victoria</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pacuszka</surname>
                    <given-names>Ewa</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bech</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Minnion</surname>
                    <given-names>James</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tharakan</surname>
                    <given-names>George</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5873-3432</contrib-id>
                  <name>
                    <surname>Tan</surname>
                    <given-names>Tricia</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Veldhuis</surname>
                    <given-names>Johannes</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0002">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Abbara</surname>
                    <given-names>Ali</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Comninos</surname>
                    <given-names>Alexander N</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                  <xref ref-type="aff" rid="AF0003">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5950-4316</contrib-id>
                  <name>
                    <surname>Dhillo</surname>
                    <given-names>Waljit S</given-names>
                  </name>
                  <xref ref-type="aff" rid="AF0001">1</xref>
                  <xref ref-type="corresp" rid="c1"/>
                  <!--<email>w.dhillo@imperial.ac.uk</email>-->
                </contrib>
              </contrib-group>
              <aff id="AF0001"><label>1</label><institution>Section of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London,</institution> London, <country country="GB">UK</country></aff>
              <aff id="AF0002"><label>2</label><institution>Department of Internal Medicine,</institution> Mayo Clinic, Minnesota</aff>
              <aff id="AF0003"><label>3</label><institution>Department of Endocrinology, Imperial College Healthcare NHS Trust,</institution> London, <country country="GB">UK</country></aff>
              <author-notes>
                <corresp id="c1"><bold><italic>Correspondence and Reprint Requests</italic>:</bold> Prof. Waljit S. Dhillo, Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, London W12 0NN, UK. E-mail: <email>w.dhillo@imperial.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>3</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2019-10-19">
                <day>19</day>
                <month>10</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>19</day>
                <month>10</month>
                <year>2019</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
              <volume>105</volume>
              <issue>3</issue>
              <fpage>833</fpage>
              <lpage>838</lpage>
              <history>
                <date date-type="received">
                  <day>08</day>
                  <month>7</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>02</day>
                  <month>10</month>
                  <year>2019</year>
                </date>
                <date date-type="corrected-typeset">
                  <day>16</day>
                  <month>2</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Endocrine Society 2019.</copyright-statement>
                <copyright-year>2019</copyright-year>
                <license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="dgz103.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s0100">
                  <title>Context</title>
                  <p>Central and peripheral administration of peptide YY (PYY) has potent anorectic effects, and PYY analogs are under development as antiobesity treatments. Recent animal data suggest PYY may also influence the reproductive axis; however the effects of PYY on the human reproductive system are unknown.</p>
                </sec>
                <sec id="s0101">
                  <title>Objective</title>
                  <p>To investigate the effects of PYY administration on the reproductive axis in healthy young men.</p>
                </sec>
                <sec id="s0102">
                  <title>Design</title>
                  <p>Single-blind, randomized, placebo-controlled crossover study.</p>
                </sec>
                <sec id="s0103">
                  <title>Setting</title>
                  <p>Clinical Research Facility, Imperial College Healthcare NHS Trust.</p>
                </sec>
                <sec id="s0104">
                  <title>Participants</title>
                  <p>Eighteen healthy eugonadal men (mean age 24.1 ± 0.9 years, mean body mass index 22.2 ± 0.4 kg/m<sup>2</sup>).</p>
                </sec>
                <sec id="s0105">
                  <title>Intervention</title>
                  <p>Eight-hour intravenous infusion of 0.4 pmol/kg/min PYY<sub>3-36</sub> or rate-matched vehicle infusion.</p>
                </sec>
                <sec id="s0106">
                  <title>Main Outcome Measures</title>
                  <p>Number of luteinizing hormone (LH) pulses, LH, follicle stimulating hormone (FSH), and testosterone levels.</p>
                </sec>
                <sec id="s0107">
                  <title>Results</title>
                  <p>The number of LH pulses (mean number of LH pulses/8 hours: PYY 4.4 ± 0.3 vs vehicle 4.4 ± 0.4, <italic>P</italic> &gt; .99), LH area under the curve (AUC) (PYY 1503 ± 79 IU.min/L vs vehicle 1574 ± 86 IU.min/L, <italic>P</italic> = .36), FSH AUC (PYY 1158 ± 513 IU.min/L vs vehicle 1199 ± 476 IU.min/L, <italic>P</italic> = .49) and testosterone AUC (PYY 10 485 ± 684 IU.min/L vs vehicle 11 133 ± 803 IU.min/L, <italic>P</italic> = .24) were similar during PYY and vehicle infusions.</p>
                </sec>
                <sec id="s0108">
                  <title>Conclusions</title>
                  <p>Acute intravenous infusion of 0.4 pmol/kg/min PYY does not affect the reproductive axis in healthy men.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>peptide-YY</kwd>
                <kwd>luteinizing hormone</kwd>
                <kwd>follicle stimulating hormone</kwd>
                <kwd>testosterone</kwd>
                <kwd>reproduction</kwd>
              </kwd-group>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>NIHR Biomedical Research Centre</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>MR/M004171/1</award-id>
                  <award-id>MR/N020472/1</award-id>
                  <award-id>MR/R000484/1</award-id>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Wellcome Trust</institution>
                      <institution-id institution-id-type="DOI">10.13039/100010269</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>CS-2018-18-ST2-002</award-id>
                  <award-id>RP-2014-05-001</award-id>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="6"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>Obesity is a major global health problem that increases morbidity (<xref rid="CIT0001" ref-type="bibr">1</xref>), mortality (<xref rid="CIT0002" ref-type="bibr">2</xref>), and has a significant detrimental impact on healthcare budgets (<xref rid="CIT0003" ref-type="bibr">3</xref>). In 2016, 39% of adults and 13% of children worldwide were obese, and more people died as a consequence of obesity than undernutrition (<xref rid="CIT0004" ref-type="bibr">4</xref>). Bariatric surgery is the most effective treatment for obesity, but it is not universally available or acceptable to patients, and postprocedure complications limit its use (<xref rid="CIT0005" ref-type="bibr">5</xref>). Lifestyle modifications are difficult to maintain outside research settings with extended care required for weight loss maintenance (<xref rid="CIT0006" ref-type="bibr">6</xref>). Therefore, medications remain the mainstay of obesity management. An emerging class of antiobesity medication is peptide YY (PYY) analogs, with over 20 patents for this new class of medication listed on the European Patent Register (<xref rid="CIT0007" ref-type="bibr">7</xref>).</p>
            <p>Physiologically, PYY is predominantly produced by intestinal L cells in response to nutrient ingestion. Resulting rapid elevations in circulating postprandial PYY levels are directly proportional to the size of the ingested meal (<xref rid="CIT0008" ref-type="bibr">8</xref>, <xref rid="CIT0009" ref-type="bibr">9</xref>). PYY has a powerful anorectic effect via activation of central Y2 receptors (<xref rid="CIT0010" ref-type="bibr">10</xref>) with central and peripheral administration of PYY dose-dependently reducing food intake by up to 25% in rodents (<xref rid="CIT0010" ref-type="bibr">10</xref>). In normal weight, overweight, and obese people, administration of PYY potently suppresses appetite and reduces food intake (by ~30%) (<xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0011" ref-type="bibr">11</xref>).</p>
            <p>Furthermore, there is evidence that PYY may have other effects in addition to weight loss, which are imperative to decipher given the ongoing development of PYY analogs as antiobesity therapies. PYY stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from isolated prepubertal rat pituitaries (<xref rid="CIT0012" ref-type="bibr">12</xref>). Additionally, PYY administration increases LH and FSH levels in adult male rats, an effect that is potentiated by fasting (<xref rid="CIT0013" ref-type="bibr">13</xref>). Secondary hypogonadism occurs in up to 40% of obese men, which is associated with higher body weight and increased insulin resistance (<xref rid="CIT0014" ref-type="bibr">14</xref>). Therefore, the anorectic effects of PYY, and the potential to stimulate reproductive hormone release, would be advantageous in the treatment of obesity with coexisting hypogonadism.</p>
            <p>As there are no reports of the effects of PYY on the reproductive system in humans, we undertook a randomized single-blinded placebo-controlled crossover study to determine the effects of PYY administration on reproductive hormone release in healthy men. Fertility is dependent on absolute reproductive hormone levels as well as LH pulsatility (<xref rid="CIT0015" ref-type="bibr">15</xref>). Therefore, we sought to determine the effect of PYY administration on several key parameters of LH secretion, as well as circulating FSH and testosterone levels.</p>
            <sec sec-type="materials" id="s1">
              <title>Materials and Methods</title>
              <sec id="s2">
                <title>Study participants</title>
                <p>This study was approved by the West London Research Ethics Committee (16/LO/0391) and performed in accordance with the Declaration of Helsinki. Healthy eugonadal men (aged 18–40 years) were recruited via online and print advertisements. Written informed consent was obtained from each participant prior to study enrolment. Exclusion criteria included: body mass index (BMI) &lt;18.5 or &gt;25 kg/m<sup>2</sup>, history of medical and psychological conditions, use of prescription, recreational or investigational drugs within the preceding 2 months, blood donation within 3 months of study participation, ingestion or inhalation of nicotine-containing substances within 3 months, alcoholism, and history of cancer.</p>
              </sec>
              <sec id="s3">
                <title>Study visits</title>
                <p>Each participant attended 2 study visits, 1 for PYY administration and 1 for vehicle administration. Infusion order was randomized and participants were blinded to the infusion identity. PYY infusions were prepared by dissolving PYY<sub>3-36</sub> (Bachem, UK) in 1 ml of 0.9% NaCl (Braun, UK) and adding the PYY solution to 49 ml of Gelofusine (Braun, UK). PYY was infused at a rate of 0.4 pmol/kg/min, a dose previously established to be biologically active in humans (<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0016" ref-type="bibr">16</xref>). Vehicle infusions consisted of Gelofusine (Braun, UK), administered at the equivalent rate to the PYY infusion for each participant.</p>
                <p>After an overnight fast starting at 10 <sc>pm</sc> on the night before each study visit, each participant ate a standardized 200 kcal breakfast (1 pot of Oat So Simple® porridge, Quaker Food Products, UK) at 6 <sc>am</sc> on the morning of each study visit. The participants arrived at the Clinical Research Facility at 8.15 <sc>am</sc> on the morning of each study visit. After a period of acclimatization, 2 intravenous cannulae (1 in each arm) were inserted (1 for blood samples and 1 to administer the infusion). Following baseline sampling, PYY or vehicle infusion was started at T = 0 minutes (9 <sc>am</sc>) and infused until T = 500 minutes. Visual analog scales (VASs, 0–10 cm), used to measure participants’ self-reported nausea, were performed at T = –15 minutes, T = 240 minutes, and T = 470 minutes. Blood samples were taken at 10-minute intervals throughout the study (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Participants were not allowed to eat during the infusion until after T = 480 minutes.</p>
                <fig id="F1" orientation="portrait" position="float">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Study visit protocol. </p>
                    <p>After a period of acclimatization following their arrival at the Clinical Research Facility, 18 healthy men (mean age 24.1 ± 0.9 years, mean body mass index 22.2 ± 0.4 kg/m<sup>2</sup>), received an 8-hour infusion of 0.4 pmol/kg/min Peptide YY<sub>3-36</sub> (PYY) during one study visit and rate-matched vehicle infusion at a second study visit, in random order. Blood samples were taken at ten-minute intervals starting from 30 minutes before the infusion was started (ie, T = –30 minutes). Visual analog scales (VASs) were completed by the participants pre-infusion (T = –15 minutes), mid-infusion (T = 240 minutes) and prior to the end of the infusion (T = 470 minutes).</p>
                  </caption>
                  <graphic xlink:href="dgz103f0001"/>
                </fig>
              </sec>
              <sec id="s4">
                <title>Biochemical analyses</title>
                <p>PYY was measured using an established in-house radioimmunoassay (<xref rid="CIT0017" ref-type="bibr">17</xref>). Serum insulin, plasma glucose, serum LH, serum FSH, and serum testosterone were measured in the Clinical Chemistry Laboratory of Imperial College Healthcare NHS Trust on the automated Abbott Architect® platform. Chemiluminescent immunoassays were used to measure serum insulin (intra-assay and interassay coefficient of variation (CV): ≤7%), serum LH (intra-assay and interassay CV: ≤5%), serum FSH (intra-assay and interassay CV: ≤10%), and serum testosterone (intra-assay and interassay CV: ≤8%). Plasma glucose was measured using a colorimetric hexokinase assay (intra-assay and interassay CV: ≤2%).</p>
              </sec>
              <sec id="s5">
                <title>Statistical analysis</title>
                <p>LH pulsatility was determined using blinded deconvolution analysis (<xref rid="CIT0018" ref-type="bibr">18</xref>). Longitudinal nonindependent data were analyzed with generalized estimating equations (GEEs). Paired t-tests were performed on parametric data and Wilcoxon matched pairs sign rank tests were performed on paired nonparametric data. STATA 14.1 (STATACorp, USA) and Prism 8.0.2 (GraphPad, USA) software were used to perform statistical analyses. <italic>P</italic>-values &lt;.05 were considered statistically significant. Data are presented as mean ± standard error of the mean.</p>
              </sec>
            </sec>
            <sec id="s6">
              <title>Results</title>
              <sec id="s7">
                <title>Participants</title>
                <p>Twenty-four healthy men were recruited, with 18 men (mean age 24.1 ± 0.9 years, mean BMI 22.2 ± 0.4 kg/m<sup>2</sup>) completing the study. Four men did not complete the study due to their other commitments and 2 were unable to tolerate the PYY infusion due to nausea. Data from the 18 men who completed the study are included in the analyses below.</p>
              </sec>
              <sec id="s8">
                <title>Effects of PYY on LH levels</title>
                <p>There was no significant difference between serum LH levels during PYY infusion and during vehicle infusion (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). Intravenous PYY infusion did not alter LH pulsatility (mean number of LH pulses/8 hours: PYY 4.4 ± 0.3 vs vehicle 4.4 ± 0.4, <italic>P</italic> &gt; .99). Furthermore, mean LH (PYY 2.8 ± 0.2 IU/L vs vehicle 3.0 ± 0.2 IU/L, <italic>P</italic> = .31) and LH area under the curve (AUC) (PYY 1503 ± 79 IU.min/L vs vehicle 1574 ± 86 IU.min/L, <italic>P</italic> = .36) were not significantly altered by PYY infusion.</p>
                <fig id="F2" orientation="portrait" position="float">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Effects of intravenous peptide YY (PYY) administration (0.4 pmol/kg/min PYY<sub>3-36</sub> for 8 hours) on reproductive hormone secretion in 18 healthy men. (<bold>A)</bold> Serum luteinizing hormone (LH) levels were similar throughout PYY and rate-matched vehicle infusions (generalized estimating equation (GEE), <italic>P</italic> = .50). (<bold>B)</bold> Serum follicle-stimulating hormone (FSH) levels were similar throughout PYY and rate-matched vehicle infusions (GEE, <italic>P</italic> = .79). (<bold>C)</bold> Serum testosterone levels were similar throughout PYY and rate-matched vehicle infusions (GEE, <italic>P</italic> = .53).</p>
                  </caption>
                  <graphic xlink:href="dgz103f0002"/>
                </fig>
              </sec>
              <sec id="s9">
                <title>Effects of PYY on FSH levels</title>
                <p>Similar to LH, there was no significant difference between serum FSH levels during PYY infusion and during vehicle infusion (<xref ref-type="fig" rid="F2">Fig. 2B</xref>). Additionally, mean FSH (PYY 2.2 ± 0.2 IU/L vs vehicle 2.3 ± 0.2 IU/L, <italic>P</italic> = .48) and FSH AUC (PYY 1158 ± 513 IU.min/L vs vehicle 1199 ± 476 IU.min/L, <italic>P</italic> = .49) did not significantly differ between PYY and vehicle infusion.</p>
              </sec>
              <sec id="s10">
                <title>Effects of PYY on testosterone levels</title>
                <p>Consistent with the absence of an effect on LH and FSH secretion, intravenous PYY infusion did not alter serum testosterone levels during the 8-hour infusion, and diurnal variation in testosterone levels was unchanged by PYY (<xref ref-type="fig" rid="F2">Fig. 2C</xref>). Similarly, mean testosterone (PYY 19.8 ± 1.3 IU/L vs vehicle 21.1 ± 1.5 IU/L, <italic>P</italic> = .24) and testosterone AUC (PYY 10 485 ± 684 IU.min/L vs vehicle 11 133 ± 803 IU.min/L, <italic>P</italic> = .24) were unaffected by PYY infusion.</p>
              </sec>
              <sec id="s11">
                <title>Effects of PYY on nausea and fullness</title>
                <p>PYY infusion resulted in significantly higher circulating PYY levels than vehicle infusion (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). PYY is known to cause nausea at biologically active doses (<xref rid="CIT0009" ref-type="bibr">9</xref>). Therefore, we assessed the effect of the PYY infusion on nausea. PYY infusion resulted in significantly higher self-reported nausea than vehicle infusion over the 8-hour study period peaking midinfusion (<xref ref-type="fig" rid="F3">Fig. 3B</xref>). However, the absolute nausea levels were low (ie, ~2/10 cm). Additionally, PYY infusion resulted in a smaller reduction in the feeling of fullness at T = 480 minutes compared with vehicle infusion (<xref ref-type="fig" rid="F3">Fig. 3C</xref>).</p>
                <fig id="F3" orientation="portrait" position="float">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Effects of intravenous peptide YY (PYY) administration (0.4 pmol/kg/min PYY<sub>3-36</sub> for 8 hours) on plasma PYY levels, nausea and fullness in 18 healthy men. (<bold>A)</bold> PYY infusion resulted in significantly higher plasma PYY levels compared to vehicle infusion (generalized estimating equation (GEE), ****<italic>P</italic> &lt; .0001). (<bold>B)</bold> Self-reported nausea, measured using a 0–10 cm visual analog scale (VAS), was increased by PYY infusion compared to vehicle infusion (generalized estimating equation (GEE), ***<italic>P</italic> &lt; .001). <bold>C:</bold> Self-reported fullness, measured using a 0–10 cm visual analog scale (VAS), reduced by a lesser extent at T = 480 minutes during PYY infusion compared with vehicle infusion (Wilcoxon matched-pairs signed rank test, **<italic>P</italic> = .01).</p>
                  </caption>
                  <graphic xlink:href="dgz103f0003"/>
                </fig>
              </sec>
            </sec>
            <sec id="s12">
              <title>Discussion</title>
              <p>This is the first study investigating the effects of PYY on the reproductive system in humans. Our study demonstrates that, an 8-hour infusion of 0.4 pmol/kg/min PYY<sub>3-36</sub> does not alter LH pulsatility in healthy men and does not change circulating levels of LH, FSH, and testosterone. This is in contrast to rodent studies, where PYY administration (centrally or peripherally) had specific effects on reproductive hormone levels depending on pubertal status and route of administration as follows. Incubation of pituitaries from prepubertal rats with PYY results in increased LH and FSH secretion within 60 minutes (<xref rid="CIT0012" ref-type="bibr">12</xref>). However, incubation of PYY with hypothalamic fragments from prepubertal and adult rats results in reduced gonadotrophin-releasing hormone (GnRH) secretion (<xref rid="CIT0012" ref-type="bibr">12</xref>, <xref rid="CIT0013" ref-type="bibr">13</xref>). Central administration of PYY to prepubertal rats inhibited LH secretion but did not affect FSH secretion (<xref rid="CIT0012" ref-type="bibr">12</xref>). In contrast, intracerebroventricular administration of PYY increases LH and FSH in fed and fasted adult male rats, and co-administration of a GnRH antagonist abolishes these effects (<xref rid="CIT0013" ref-type="bibr">13</xref>). However, peripheral administration of PYY (via intraperitoneal injection) has no effect on LH secretion but increases FSH secretion in prepubertal male rats (<xref rid="CIT0012" ref-type="bibr">12</xref>).</p>
              <p>It is possible that no effect on reproductive hormone secretion was detected in response to PYY administration in this study due to the peripheral route of administration. As outlined in the rodent studies above, central administration of PYY stimulates gonadotrophin secretion in adult male rats (<xref rid="CIT0013" ref-type="bibr">13</xref>), whereas peripheral administration has been shown to increase FSH (but not LH) in prepubertal male rats (<xref rid="CIT0012" ref-type="bibr">12</xref>).</p>
              <p>The anorectic effects of PYY are thought to be mediated by agonism of the Y2 receptor (<xref rid="CIT0010" ref-type="bibr">10</xref>, <xref rid="CIT0019" ref-type="bibr">19</xref>). However, the effect of PYY on reproductive hormone secretion may not occur via the Y2 receptor. Central administration of a selective Y2 receptor agonist reduces LH and FSH secretion in adult male rats, while administration of a Y2 receptor antagonist increases LH and FSH secretion in adult male rats (<xref rid="CIT0020" ref-type="bibr">20</xref>). In contrast, central administration of PYY to adult male rats stimulates LH and FSH secretion (<xref rid="CIT0013" ref-type="bibr">13</xref>). In the present study, peripheral PYY administration increased nausea but had no effect on reproductive hormone levels. Therefore, Y2 agonism in healthy men does not modulate reproductive hormone secretion.</p>
              <p>Although participants were instructed to fast overnight and eat a standardized breakfast (which was provided to them in advance), the overnight fast and consumption of the standardized breakfast were not monitored. However, this limitation is unlikely to have significantly influenced the results as all participants were closely monitored as fasting throughout the 8-hour infusion and no reproductive hormone changes were evident at any point.</p>
              <p>In this present study, PYY administration did not alter LH, FSH, and testosterone levels in healthy (non-obese) men. Further studies are required to determine the effects of PYY on reproductive hormone secretion in obese people, ie, the target population for PYY-based therapeutic agents.</p>
            </sec>
            <sec id="s13">
              <title>Conclusions</title>
              <p>Although animal data suggest that PYY affects reproductive hormone secretion, our data demonstrate that in humans, acute administration of a biologically active dose of PYY does not have an adverse effect on LH pulsatility and does not alter levels of LH, FSH, and testosterone. This has important clinical and safety implications for the continuing development of PYY analogs for the treatment of obesity.</p>
            </sec>
          </body>
          <back>
            <glossary>
              <def-list>
                <title>Abbreviations</title>
                <def-item>
                  <term>BMI</term>
                  <def>
                    <p>body mass index</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GEE</term>
                  <def>
                    <p>generalized estimating equation</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GnRH</term>
                  <def>
                    <p>gonadotrophin-releasing hormone</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FSH</term>
                  <def>
                    <p>follicle-stimulating hormone</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LH</term>
                  <def>
                    <p>luteinizing hormone</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PYY</term>
                  <def>
                    <p>peptide YY</p>
                  </def>
                </def-item>
                <def-item>
                  <term>VAS</term>
                  <def>
                    <p>visual analog scale</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <sec id="s0110">
              <title>Acknowledgments</title>
              <p>This article presents independent research funded by the NIHR and supported by the NIHR CRF and BRC at Imperial College Healthcare NHS Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.</p>
              <p><bold><italic>Financial Support:</italic></bold> The Section of Endocrinology and Investigative Medicine is funded by grants from the Medical Research Council (MRC), Biotechnology and Biological Sciences Research Council (BBSRC), National Institute for Health Research (NIHR), an Integrative Mammalian Biology (IMB) Capacity Building Award, an FP7- HEALTH- 2009-241592 EuroCHIP grant and is supported by the NIHR Biomedical Research Centre Funding Scheme. C.I. is funded by an MRC Clinical Research Training Fellowship (MR/M004171/1). D.P. is supported by NIHR CLRN funding. R.R. is funded by an MRC Clinical Research Training Fellowship (MR/N020472/1). L.Y. is funded by an MRC Clinical Research Training Fellowship (MR/R000484/1). T.T. is supported by grants from the MRC and Wellcome Trust. A.A. is funded by an NIHR Clinician Scientist Award (CS-2018-18-ST2-002). A.N.C. is funded by the NHS. W.S.D. is funded by an NIHR Professorship (RP-2014-05-001).</p>
            </sec>
            <sec id="s0111">
              <title>Additional Information</title>
              <p><bold><italic>Disclosure Summary:</italic></bold> The authors have nothing to disclose.</p>
              <p><bold><italic>Data Availability:</italic></bold> The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.</p>
            </sec>
            <ref-list id="r1">
              <title>References</title>
              <ref id="CIT0001">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guh</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Bansback</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Amarsi</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Birmingham</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Anis</surname><given-names>AH</given-names></name></person-group><article-title>The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis</article-title>. <source>BMC Public Health.</source><year>2009</year>;<volume>9</volume>:<fpage>88</fpage>.<pub-id pub-id-type="pmid">19320986</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0002">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Global</surname><given-names>BMIMC</given-names></name>, <name name-style="western"><surname>Di Angelantonio</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bhupathiraju Sh</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Wormser</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kaptoge</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group><article-title>Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents</article-title>. <source>Lancet.</source><year>2016</year>;<volume>388</volume>(<issue>10046</issue>):<fpage>776</fpage>–<lpage>786</lpage>.<pub-id pub-id-type="pmid">27423262</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0003">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kent</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Reeves</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>; <person-group><collab>Million Women Study collaborators</collab></person-group><article-title>Hospital costs in relation to body-mass index in 1·1 million women in England: a prospective cohort study</article-title>. <source>Lancet Public Health.</source><year>2017</year>;<volume>2</volume>(<issue>5</issue>):<fpage>e214</fpage>–<lpage>e222</lpage>.<pub-id pub-id-type="pmid">29253487</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0004">
                <label>4.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Organization</surname><given-names>WH.</given-names></name></person-group><source>Obesity and Overweight Factsheet 2018</source>. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight">https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight</ext-link>. Accessed 25 May 2019.</mixed-citation>
              </ref>
              <ref id="CIT0005">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puzziferri</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Roshek</surname><given-names>TB</given-names><suffix>3rd</suffix></name>, <name name-style="western"><surname>Mayo</surname><given-names>HG</given-names></name>, <name name-style="western"><surname>Gallagher</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Belle</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Livingston</surname><given-names>EH</given-names></name></person-group><article-title>Long-term follow-up after bariatric surgery: a systematic review</article-title>. <source>JAMA.</source><year>2014</year>;<volume>312</volume>(<issue>9</issue>):<fpage>934</fpage>–<lpage>942</lpage>.<pub-id pub-id-type="pmid">25182102</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0006">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middleton</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Patidar</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Perri</surname><given-names>MG</given-names></name></person-group><article-title>The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis</article-title>. <source>Obes Rev.</source><year>2012</year>;<volume>13</volume>(<issue>6</issue>):<fpage>509</fpage>–<lpage>517</lpage>.<pub-id pub-id-type="pmid">22212682</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0007">
                <label>7.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Office</surname><given-names>EP.</given-names></name></person-group><source>European Patent Register</source>. <ext-link ext-link-type="uri" xlink:href="https://register.epo.org/smartSearch?searchMode=smart&amp;query=peptide+yy">https://register.epo.org/smartSearch?searchMode=smart&amp;query=peptide+yy</ext-link>. Accessed 25 May 2019.</mixed-citation>
              </ref>
              <ref id="CIT0008">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gribble</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Reimann</surname><given-names>F</given-names></name></person-group><article-title>Enteroendocrine cells: chemosensors in the intestinal epithelium</article-title>. <source>Annu Rev Physiol.</source><year>2016</year>;<volume>78</volume>:<fpage>277</fpage>–<lpage>299</lpage>.<pub-id pub-id-type="pmid">26442437</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0009">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Degen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Oesch</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Casanova</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group><article-title>Effect of peptide YY3-36 on food intake in humans</article-title>. <source>Gastroenterology.</source><year>2005</year>;<volume>129</volume>(<issue>5</issue>):<fpage>1430</fpage>–<lpage>1436</lpage>.<pub-id pub-id-type="pmid">16285944</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0010">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batterham</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Cowley</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Small</surname><given-names>CJ</given-names></name>, <etal>et al</etal></person-group><article-title>Gut hormone PYY(3-36) physiologically inhibits food intake</article-title>. <source>Nature.</source><year>2002</year>;<volume>418</volume>(<issue>6898</issue>):<fpage>650</fpage>–<lpage>654</lpage>.<pub-id pub-id-type="pmid">12167864</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0011">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batterham</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Ellis</surname><given-names>SM</given-names></name>, <etal>et al</etal></person-group><article-title>Inhibition of food intake in obese subjects by peptide YY3-36</article-title>. <source>N Engl J Med.</source><year>2003</year>;<volume>349</volume>(<issue>10</issue>):<fpage>941</fpage>–<lpage>948</lpage>.<pub-id pub-id-type="pmid">12954742</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0012">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Fernandez</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Aguilar</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Tena-Sempere</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pinilla</surname><given-names>L</given-names></name></person-group><article-title>Effects of polypeptide YY(3-36) upon luteinizing hormone-releasing hormone and gonadotropin secretion in prepubertal rats: in vivo and in vitro studies</article-title>. <source>Endocrinology.</source><year>2005</year>;<volume>146</volume>(<issue>3</issue>):<fpage>1403</fpage>–<lpage>1410</lpage>.<pub-id pub-id-type="pmid">15564330</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0013">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinilla</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fernández-Fernández</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vigo</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group><article-title>Stimulatory effect of PYY-(3-36) on gonadotropin secretion is potentiated in fasted rats</article-title>. <source>Am J Physiol Endocrinol Metab.</source><year>2006</year>;<volume>290</volume>(<issue>6</issue>):<fpage>E1162</fpage>–<lpage>E1171</lpage>.<pub-id pub-id-type="pmid">16390861</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0014">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dandona</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dhindsa</surname><given-names>S</given-names></name></person-group><article-title>Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity</article-title>. <source>J Clin Endocrinol Metab.</source><year>2011</year>;<volume>96</volume>(<issue>9</issue>):<fpage>2643</fpage>–<lpage>2651</lpage>.<pub-id pub-id-type="pmid">21896895</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0015">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knobil</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Plant</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Wildt</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Belchetz</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Marshall</surname><given-names>G</given-names></name></person-group><article-title>Control of the rhesus monkey menstrual cycle: permissive role of hypothalamic gonadotropin-releasing hormone</article-title>. <source>Science.</source><year>1980</year>;<volume>207</volume>(<issue>4437</issue>):<fpage>1371</fpage>–<lpage>1373</lpage>.<pub-id pub-id-type="pmid">6766566</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0016">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neary</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Small</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Druce</surname><given-names>MR</given-names></name>, <etal>et al</etal></person-group><article-title>Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively</article-title>. <source>Endocrinology.</source><year>2005</year>;<volume>146</volume>(<issue>12</issue>):<fpage>5120</fpage>–<lpage>5127</lpage>.<pub-id pub-id-type="pmid">16150917</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0017">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Salem</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Troke</surname><given-names>RC</given-names></name>, <etal>et al</etal></person-group><article-title>Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose</article-title>. <source>J Clin Endocrinol Metab.</source><year>2014</year>;<volume>99</volume>(<issue>11</issue>):<fpage>E2317</fpage>–<lpage>E2324</lpage>.<pub-id pub-id-type="pmid">25144632</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0018">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayasena</surname><given-names>CN</given-names></name>, <name name-style="western"><surname>Abbara</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Veldhuis</surname><given-names>JD</given-names></name>, <etal>et al</etal></person-group><article-title>Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of Kisspeptin-54</article-title>. <source>J Clin Endocrinol Metab.</source><year>2014</year>;<volume>99</volume>(<issue>6</issue>):<fpage>E953</fpage>–<lpage>E961</lpage>.<pub-id pub-id-type="pmid">24517142</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0019">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbott</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Small</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Kennedy</surname><given-names>AR</given-names></name>, <etal>et al</etal></person-group><article-title>Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake</article-title>. <source>Brain Res.</source><year>2005</year>;<volume>1043</volume>(<issue>1-2</issue>):<fpage>139</fpage>–<lpage>144</lpage>.<pub-id pub-id-type="pmid">15862527</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0020">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinilla</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fernández-Fernández</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Roa</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Castellano</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Tena-Sempere</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Aguilar</surname><given-names>E</given-names></name></person-group><article-title>Selective role of neuropeptide Y receptor subtype Y2 in the control of gonadotropin secretion in the rat</article-title>. <source>Am J Physiol Endocrinol Metab.</source><year>2007</year>;<volume>293</volume>(<issue>5</issue>): <fpage>E1385</fpage>–<lpage>E1392</lpage>.<pub-id pub-id-type="pmid">17785504</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
